News | Artificial Intelligence | April 05, 2023

A worklist reprioritization tool with artificial intelligence reduced both report turnaround time and wait time for pulmonary embolus-positive CT pulmonary angiography examinations

54-year-old with mild chest pain for 3 days who underwent CTPA to assess acute PE

54-year-old with mild chest pain for 3 days who underwent CTPA to assess acute PE. A, Axial image shows nonocclusive filling defect (arrow) in right lower lobe basal trunk. AI classified examination positive for PE. B, Activation map shows location corresponding to PE (arrow) identified by AI. Examination reprioritized on radiologist reading worklist, given positive result from AI tool. Wait time: 6.7 mins; read time: 17.2 mins; turnaround time: 23.9 mins. 


April 5, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), a worklist reprioritization tool with artificial intelligence reduced both report turnaround time and wait time for pulmonary embolus-positive CT pulmonary angiography examinations. 

“By assisting radiologists in providing rapid diagnoses, the artificial intelligence (AI) tool could potentially enable earlier interventions for acute pulmonary embolus (PE),” concluded lead researcher Kiran Batra, MD, from the department of radiology at University of Texas Southwestern Medical Center in Dallas.   

Batra et al.’s AJR accepted manuscript included patients who underwent CT pulmonary angiography (CTPA) before (October 1, 2018–March 31, 2019) and after (October 1, 2019–March 31, 2020) implementing an FDA-approved AI tool that reprioritized CTPA examinations atop radiologists’ reading list, if acute PE was detected. Timestamps from EMR and dictation systems were then utilized to determine three times: wait (examination completion to report initiation), read (report initiation to availability), as well as report turnaround (sum of wait and read). Times for PE positive reports, using final imaging for reference, were compared between periods.  

Ultimately, the authors’ AI-driven worklist reprioritization tool was associated with significantly shorter report turnaround (47.6 vs. 59.9 mins) and wait (21.4 vs. 33.4 mins) times—though no significant difference in reading time (26.3 vs. 26.5 mins)—for CTPA reports positive for acute PE, compared to reports from before AI implementation. 

“During regular hours,” the authors of this AJR accepted manuscript added, “the reduction in wait time was observed for examinations with routine, but not urgent or stat, priority.” 

For more information: www.arrs.org 


Related Content

News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Computed Tomography (CT)

April 2, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for True ...

Time April 03, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
News | Computed Tomography (CT)

March 30, 2026 — HCA Healthcare’s Good Samaritan Hospital is the first hospital in the Bay Area to implement Lumina 3D ...

Time April 01, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Time March 30, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 25, 2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
Subscribe Now